Antifibrotic effect and long‐term outcome of <scp>SGLT</scp> 2 inhibitors in patients with <scp>NAFLD</scp> complicated by diabetes mellitus-Reference-Cited by-同舟云学术

Antifibrotic effect and long‐term outcome of SGLT 2 inhibitors in patients with NAFLD complicated by diabetes mellitus

Published:2022-08-30 Issue:11 Volume:6 Page:3073-3082
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Arai Taeang¹,Atsukawa Masanori¹,Tsubota Akihito²,Mikami Shigeru³,Haruki Uojima⁴^ORCID,Yoshikata Keiichiro¹,Ono Hiroki¹,Kawano Tadamichi¹,Yoshida Yuji⁵,Tanabe Tomohide¹,Okubo Tomomi⁵,Hayama Korenobu⁵,Nakagawa‐Iwashita Ai¹,Itokawa Norio¹,Kondo Chisa¹,Kaneko Keiko¹,Nagao Mototsugu⁶,Inagaki Kyoko⁶,Fukuda Izumi⁶,Sugihara Hitoshi⁶,Iwakiri Katsuhiko¹

Affiliation:

1. Division of Gastroenterology and Hepatology Nippon Medical School Tokyo Japan

2. Core Research Facilities for Basic Science, Research Center for Medical Sciences The Jikei University School of Medicine Tokyo Japan

3. Division of Gastroenterology, Department of Internal Medicine Kikkoman General Hospital Miyazaki Noda Japan

4. Department of Gastroenterology, Internal Medicine Kitasato University School of Medicine Sagamihara Japan

5. Division of Gastroenterology Nippon Medical School Chiba Hokusoh Hospital Chiba Japan

6. Division of Endocrinology, Diabetes and Metabolism Nippon Medical School Tokyo Japan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.2069

Reference50 articles.

1. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

2. Nonalcoholic fatty liver disease: From steatosis to cirrhosis

3. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

4. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

5. Long‐term outcomes of non‐alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors;Advances in Medical Sciences;2024-09

2. Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients;Journal of Clinical Medicine;2024-08-21

3. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches;International Journal of Molecular Sciences;2024-08-10

4. Association between triglyceride to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease and liver fibrosis in American adults: an observational study from the National Health and Nutrition Examination Survey 2017–2020;Frontiers in Endocrinology;2024-07-16

5. What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives;International Journal of Molecular Sciences;2024-07-15